Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 43, Issue 1, Pages 34-41Publisher
SPRINGER
DOI: 10.1007/s00259-015-3188-1
Keywords
Prostate cancer; Ga-68-PSMA ligand PET/CT; Radiotherapy planning; Individualized radiotherapy
Funding
- Klaus-Tschira-Stiftung [00.198.2012]
Ask authors/readers for more resources
Purpose Radiotherapy is the main therapeutic approach besides surgery of localized prostate cancer. It relies on risk stratification and exact staging. This report analyses the potential of [Ga-68]Glu-urea-Lys(Ahx)-HBED-CC (Ga-68-PSMA-11), a new positron emission tomography (PET) tracer targeting prostate-specific membrane antigen (PSMA) for prostate cancer staging and individualized radiotherapy planning. Methods A cohort of 57 patients with prostate cancer scanned with Ga-68-PSMA-11 PET/CT for radiotherapy planning was retrospectively reviewed; 15 patients were at initial diagnosis and 42 patients at time of biochemical recurrence. Staging results of conventional imaging, including bone scintigraphy, CT or MRI, were compared with Ga-68-PSMA ligand PET/CT results and the influence on radiotherapeutic management was quantified. Results Ga-68-PSMA ligand PET/CT had a dramatic impact on radiotherapy application in the presented cohort. In 50.8 % of the cases therapy was changed. Conclusion The presented imaging technique of Ga-68-PSMA PET/CT could be a key technology for individualized radiotherapy management in prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available